Therefore, we hypothesized that intestinal CCKBR may be a key driver to inhibit, partially, intestinal glucose absorption; indirect SGLT1 inhibition could be a novel strategy for the treatment of T2D. Here, SLC5A1 is linked to type 2 diabetes mellitus.